- Home
- COYA vs SCLXW Comparison
COYA vs SCLXW Comparison
Compare COYA & SCLXW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- COYA
- SCLXW
- Stock Information
- Founded
- COYA 2020
- SCLXW N/A
- Country
- COYA United States
- SCLXW United States
- Employees
- COYA N/A
- SCLXW 113
- Industry
- COYA Biotechnology: Pharmaceutical Preparations
- SCLXW Biotechnology: Pharmaceutical Preparations
- Sector
- COYA Health Care
- SCLXW Health Care
- Exchange
- COYA Nasdaq
- SCLXW Nasdaq
- Market Cap
- COYA N/A
- SCLXW N/A
- IPO Year
- COYA 2022
- SCLXW 2021
- Fundamental
- Price
- COYA $6.32
- SCLXW $0.25
- Analyst Decision
- COYA Strong Buy
- SCLXW
- Analyst Count
- COYA 3
- SCLXW 0
- Target Price
- COYA $16.67
- SCLXW N/A
- AVG Volume (30 Days)
- COYA 156.7K
- SCLXW N/A
- Earning Date
- COYA 11-06-2024
- SCLXW N/A
- Dividend Yield
- COYA N/A
- SCLXW N/A
- EPS Growth
- COYA N/A
- SCLXW N/A
- EPS
- COYA N/A
- SCLXW N/A
- Revenue
- COYA $9,554,315.00
- SCLXW N/A
- Revenue This Year
- COYA N/A
- SCLXW N/A
- Revenue Next Year
- COYA $54.20
- SCLXW N/A
- P/E Ratio
- COYA N/A
- SCLXW N/A
- Revenue Growth
- COYA N/A
- SCLXW N/A
- 52 Week Low
- COYA $4.75
- SCLXW N/A
- 52 Week High
- COYA $10.69
- SCLXW N/A
- Technical
- Relative Strength Index (RSI)
- COYA 39.54
- SCLXW N/A
- Support Level
- COYA $6.97
- SCLXW N/A
- Resistance Level
- COYA $7.50
- SCLXW N/A
- Average True Range (ATR)
- COYA 0.74
- SCLXW 0.00
- MACD
- COYA -0.16
- SCLXW 0.00
- Stochastic Oscillator
- COYA 5.68
- SCLXW 0.00
About SCLXW Scilex Holding Company
Scilex Holding Co is focused on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. The Company's commercial product, ZTlido (lidocaine topical system), is a prescription lidocaine topical product for the relief of pain associated with postherpetic neuralgia, which is a form of post-shingles nerve pain. It is focused on commercializing Gloperba (colchicine USP) an oral solution, a prophylactic treatment for painful gout flares in adults. The Company's three product candidates are SP-102 or SEMDEXA viscous gel formulation of a used corticosteroid for epidural injections, SP-103 a Phase 2, triple-strength formulation of ZTlido, and SP-104, 4.5 mg Delayed Burst Release Low Dose Naltrexone Hydrochloride (DBR-LDN) Capsule.